Skip to main content
. Author manuscript; available in PMC: 2018 Mar 15.
Published in final edited form as: Am J Surg Pathol. 2014 Jul;38(7):966–972. doi: 10.1097/PAS.0000000000000218

Figure 2.

Figure 2

Clinical outcome of SALL4-positive and SALL4-negative HCCs. (a) Recurrence-free survival and (b) overall survival between SALL4-positive and SALL4-negative HCCs. Black line: SALL4-negative group (n=233); grey line: SALL4-positive group (n=3). SALL4-positive cases had significantly shorter recurrence-free survival (P = 0.0115) and overall survival (P = 0.0018). (c) Recurrence-free survival and (d) overall survival between SALL4-positive HCCs and SALL4-negative HCCs but with either high tumor grade or lymphovascular invasion. Black line: SALL4-negative/high grade lymphovascular invasion group (n=64); grey line: SALL4-positive group (n=3). The two groups had no significant difference in recurrence-free survival (P = 0.9750), but the SALL4-positive group had significantly shorter overall survival (P = 0.0357). LVSI: lymphovascular invasion.